OIS XV
Co-Founder, President & CEO, Tom Reeves, presented at Ophthalmology Innovation Source in San Diego. OIS Ignite on November 20, 2025 (Power Partnerships: Alliances that Accelerate Innovation) and OIS XV on November 22, 2025 (Retina Innovation Showcase).
TORONTO, CANADA / November 25, 2025 - Ripple Therapeutics Corporation, a clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants, is pleased to announce that, earlier this year, it entered into an evaluation program and licensing option agreement with an affiliate of Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better.
Co-Founder and Chief Technology Officer, Wendy Naimark, PhD., recently presented “Overview of the Epidel Prodrug Engineered Sustained Drug Delivery Platform” at PODD: Partnership Opportunities in Drug Delivery. Click to View
